115450 — HLB Therapeutics Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for HLB Therapeutics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	42,930	43,586	42,403	52,591	54,932
Cost of Revenue
Gross Profit	6,578	5,133	8,819	7,359	10,201
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	55,316	59,955	50,349	60,629	70,594
Operating Profit	-12,386	-16,368	-7,946	-8,038	-15,662
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-17,401	-17,764	-11,573	-2,965	-22,926
Provision for Income Taxes
Net Income After Taxes	-17,401	-17,764	-11,573	-2,965	-22,926
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-16,902	-17,197	-11,354	-2,302	-22,793
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-16,902	-17,197	-11,354	-2,302	-22,793
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-276	-194	-149	-37	-171
Dividends per Share